Selfdiagnostics STD Multitest – a next generation molecular diagnostics technology based rapid test will have its first worldwide appearance at MEDICA 2017. STD Multitest is the first and only rapid chlamydia and gonorrhoea duplex test in the world. It is painless, can be used by both sexes, provides reliable results in 30 minutes and utilises technology…

Selfdiagnostics’ work within the frames of Horizon 2020 project was evaluated by European Commission experts and an interim assessment report was recently completed. The experts found that our project is compliant with H2020 regulations and has achieved objectives and milestones set for the reporting period. Experts have confidence that Selfdiagnostics will provide results with significant immediate…

FIND, a co-op partner of the World Health Organization, has included Selfdiagnostics in their 2017-2020 project pipeline for tuberculosis diagnostics. Selfdiagnostics is one of the TOP 20 projects in the Sputum-based and drug susceptibility testing area that was given this priority status. FIND evaluated Selfdiagnostics’ technology – a lab level accurate, fully disposable rapid self-test. This…

Selfdiagnostics was invited to attend the conference Innovation TRIFFT Investition (Innovation meets Investment) 2017 in Dresden 22 – 23 of June 2017 by the Minister President of Saxony Mr Stanislaw Tillich. Part of Selfdiagnostics’ R&D is based in Leipzig and we are very grateful for such acknowledgement of our work. The goal of the conference…

Selfdiagnostics Begins Production of First Molecular Diagnostic Home Test in the World after Completing Multiplexed Sexually Transmitted Diseases Product Design. Selfdiagnostics is pleased to announce that the company has successfully achieved a strategically important milestone by freezing product design of multiplexed sexually transmitted diseases MDx test. Selfdiagnostics will now move on with preparations for product…

In addition to the existing 3 applications Selfdiagnostics has filed previously, further 3 applications have been submitted in March 2017. One of the applications is in progress. All 7 patents will enable the company to protect its core technology from replication; guaranteeing continued company value and growth in the coming years.

Selfdiagnostics was presented as one of the 8 “Swimming with the Sharks” finalists at the 14th Annual Molecular Diagnostics Conference in San Francisco, USA on the 22nd February 2017 and was a one of the three winners. Our selection in this event as one of the best company demonstrates our recognition as a promising MedTech…